Preliminary Program

Sessions requiring tickets are noted throughout the 2017 ASCO Annual Meeting Preliminary Program ( = Ticketed Session). Learn more about adding the Ticketed Session package to your registration.

The Preliminary Program is current as of February 08, 2017. Discover more information on the different session types at the 2017 ASCO Annual Meeting.

7:30 AM–9:15 AM

Highlights of the Day Session

Highlights of the Day Session II

8:00 AM–9:15 AM

Education Sessions

Improving Cancer Care Through the Patient Experience: How to Use Patient-Reported Outcomes in Clinical Practice

Kathi Mooney, RN, PhD—Chair

University of Utah

Planning for the Implementations of PROs Into Clinical Practice

Daniel Sjoberg

Memorial Sloan Kettering Cancer Center

Improving Clinical Decision Making and Patient Outcomes Through Use of PRO Databases

Donna Lynn Berry, PhD, RN

Dana-Farber Cancer Institute 

Improving Outcomes at the Point of Care Using PROs

 

Management of Extracutaneous Melanomas and Nonmelanoma Skin Cancers

Richard D. Carvajal, MD

Columbia University Medical Center

Uveal Melanoma

Kim Allyson Margolin, MD

City of Hope

Mucosal Melanoma

Axel Hauschild, MD—Chair

University of Kiel

Squamous, Basal, and Merkel Cell Skin Cancers

 

Narrative As a Source of Personal Reflection and a Means of Social Change

Jane Lowe Meisel, MD—Chair

Winship Cancer Institute, Emory University

Introduction to the Use of Narrative in Oncology

Lidia Schapira, MD

Cancer Institute, Stanford Medicine

Art of Oncology and the Importance of Reflection

Ranjana Srivastava, FRACP

Monash Medical Centre

Medicine and Humanity: The Oncologist As a Writer—Using Writing for Social Change

 

Pancreatic Adenocarcinoma: Improving Prevention and Survivorship

Davendra Sohal, MD, MPH—Chair

Cleveland Clinic

Best Practices in Management of Resectable Pancreatic Cancer: Emerging Standards for Adjuvant Therapy and Surveillance

Field F. Willingham, MD, MPH

Emory School of Medicine

Hereditary Pancreatic Cancer: Surveillance and Management

Massimo Falconi, MD

Marche Polytechnic University

Multimodality Management of Borderline Resectable Pancreatic Cancer: When Is an Operation Appropriate?

 

Standard and Genomic Tools for Decision Support in Breast Cancer Treatment

Philippe L. Bedard, MD

Princess Margaret Cancer Centre

Using Molecular Tools to Make Adjuvant Endocrine Therapy Decisions

Norah Lynn Henry, MD, PhD

University of Utah

Integrating Clinicopathologic and Genomic Tools to Assist in Chemotherapy Decision-Making for Early-Stage Breast Cancer

Angela DeMichele, MD, MSCE—Chair

Abramson Cancer Center at Penn Medicine

What Is the Role and Value of Genomic Testing in the Metastatic Setting?

 

Meet the Professor Sessions

 Brain Metastases: Utilizing Genomics and Combining Treatment Modalities 

Manmeet Singh Ahluwalia, MD

Cleveland Clinic

Innovative Targeted Therapeutic Approaches in Brain Metastases

Priscilla Kaliopi Brastianos, MD

Massachusetts General Hospital

Genomic Characterization of Brain Metastases: Therapeutic Implications

 

 The Future of Oncology 

Yusuke Nakamura, MD, PhD

The University of Chicago

Genomics to Development of New Classes of Drugs Targeting Cancer Stem Cells

Lori J. Goldstein, MD

Fox Chase Cancer Center

Value of Genomics in the Era of Precision Medicine

8:00 AM–9:30 AM

Clinical Science Symposium

Gynecologic Cancer

8:00 AM–11:00 AM

Oral Abstract Sessions

Cancer Prevention, Hereditary Genetics, and Epidemiology

Genitourinary (Nonprostate) Cancer

Head and Neck Cancer

Health Services Research, Clinical Informatics, and Quality of Care

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Pediatric Oncology II

8:00 AM–11:30 AM

Poster Sessions

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Developmental Therapeutics—Immunotherapy

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Hematologic Malignancies—Plasma Cell Dyscrasia

9:45 AM–11:00 AM

Education Sessions

Are We Integrating Biologic Advances in Multiple Myeloma Into Clinical Practice?

Gareth John Morgan, MD, FRCP, FRCPath, PhD

Myeloma Institute, University of Arkansas for Medical Sciences

Integration of Genomics in Treatment: Are We There Yet?

Xavier Leleu, MD PHD

La Miletrie

Minimal Residual Disease: A Measurable and Relevant Endpoint in Treatment

Irene M. Ghobrial, MD—Chair

Dana-Farber Cancer Institute

Novel Biomarkers in Multiple Myeloma

Sagar Lonial, MD, FACP

Winship Cancer Institute, Emory University

Minimal Residual Disease Assessment: Not Relevant for Clinical Practice Yet

 

Collaborating With Advanced Practice Providers to Optimize Efficiency and Improve Care

Heather Marie Hylton, PA-C—Chair

Memorial Sloan Kettering Cancer Center

Optimizing the Inpatient Experience for Patients With Bone Marrow Transplant: The Role of the Advanced Practice Provider

Gloria Lola Smith, NP

University of Michigan 

Advanced Practice Providers in an Academic Oncology Clinic

Federico Augusto Sanchez, MD

Aurora Advanced Healthcare

The Role of Advanced Practice Providers in a Busy Community Practice

 

Metabolism and the Potential for Therapeutics

Kimryn Rathmell, MD, PhD—Chair

Vanderbilt-Ingram Cancer Center

Overview of Targets in Tumor Metabolism

Craig B. Thompson, MD

Memorial Sloan Kettering Cancer Center

Strategies to "Cut the Fuel Supply" in Cancer Therapy

Amato Giaccia, PhD

Stanford School of Medicine

Normal and Tumor-Cell Signaling and Metabolism: Clinical Implications

 

Meet the Professor Sessions

 Meet the PARP-fessors: Evolution of PARP Inhibitors in the Treatment of Ovarian Cancer 

Mansoor Raza Mirza, MD

The Finsen Centre

Clare L. Scott, MBBS, PhD, FRACP

Royal Melbourne Hospital

 

 MSI-High Colorectal Cancer and Its Management 

C. Richard Boland, MD

Baylor University Medical Center at Dallas 

Biology of Microsatellite Instability High Colorectal Cancer: Somatic Versus Germline Mutations

Heinz-Josef Lenz, MD, FACP

University of Southern California Norris Comprehensive Cancer Center 

Management of Microsatellite Instability High Colorectal Cancer: Early and Advanced Stage

9:45 AM–11:15 AM

Clinical Science Symposium

Special Clinical Science Symposium

9:45 AM–12:45 PM

Oral Abstract Session

Breast Cancer—Local/Regional/Adjuvant

11:30 AM–12:45 PM

Award Lecture

ASCO/American Cancer Society Award and Lecture

 

Poster Discussion Sessions

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

 

Education Sessions

Managing Resistance to Targeted Therapies

Justin F. Gainor, MD—Chair

Massachusetts General Hospital

EML-ALK Tyrosine Kinase Inhibitor Resistance: Mechanisms and Therapeutic Approaches

Puneeth Iyengar, MD, PhD

The University of Texas Southwestern Medical Center

Role of Radiation in Managing Resistance

Christine Marie Lovly, MD, PhD

Vanderbilt-Ingram Cancer Center

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance: Mechanisms and Therapeutic Approaches

 

Pain and Opioids in Cancer Care

Judith A. Paice, PhD, RN—Chair

Northwestern University

Opioids in Cancer Survivors: Risks, Benefits, and Challenges

Michael Bennett, MD, FRCP, FFPMRCA

The School of Medicine

Opioids in Advanced Cancer: Access, Efficacy, and Outcomes

Mark S. Wallace, MD

University of California, San Diego

Cannabis: An Alternative to Opioids?

 

Recognizing Global Oncology as an Academic Field

Lawrence N. Shulman, MD—Chair

Abramson Cancer Center at Penn Medicine

Global Oncology: Definition and Promise

Alexandru E. Eniu, MD, PhD

The Oncology Institute "Prof. Dr. Ion Chiricuta"

Global Health: Oncology in Limited-Resource Settings

Edward Lloyd Trimble, MD, MPH

National Cancer Institute at the National Institutes of Health

Global Health: It's Not About Geography, It's About Perspective

 

Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches

Edward Chu, MD—Chair

University of Pittsburgh 

Evolution of Standard Therapy for Metastatic Colorectal Cancer

Rona D. Yaeger, MD

Memorial Sloan Kettering Cancer Center

Molecular Profiling of Colorectal Cancer: What, When, and How?

Chloe Evelyn Atreya, MD, PhD

University of California, San Francisco

Translating Biomarkers Into Clinical Practice

 

Utilizing Histology and Genomics to Direct Therapy for Central Nervous System Tumors

Daniel P. Cahill, MD, PhD

Massachusetts General Hospital

Molecular Profiling and Histopathology in Glioma: How Do We Apply These Clinically?

Greg Fuller, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center

Overview of the Changes to the World Health Organization

 

Meet the Professor Sessions

 Thyroid Cancer and BRAF: Novel Systemic Therapies for Advanced Disease 

Steven I. Sherman, MD

The University of Texas MD Anderson Cancer Center

Mutation Testing in Thyroid Cancer and Optimal Molecular Targeting

Ann Wild Gramza, MD

Georgetown Lombardi Comprehensive Cancer Center

Novel Systemic Therapies for Advanced Thyroid Cancer in the Era of BRAF Testing: When Do We Need to Initiate Treatment?

 

 Treatment Approaches for the Patient With BRAF-Mutant Melanoma

Antoni Ribas, MD, PhD

University of California Los Angeles Jonsson Comprehensive Cancer Center

12:00 PM–1:00 PM

Annual Business Meeting

ASCO Annual Business Meeting (ASCO Members Only)

1:15 PM–2:30 PM

Award Lecture

Allen S. Lichter Visionary Leader Award and Lecture

Pediatric Oncology Award and Lecture and Presentation of the Partners in Progress Award

 

Poster Discussion Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 

Education Sessions

Optimal Management of Early and Advanced HER2 Breast Cancer

Sara A. Hurvitz, MD

University of California Los Angeles Health

Optimizing Neadjuvant/Adjuvant Treatment Options in Patients With HER2 Amplification

Sara M. Tolaney, MD, MPH

Dana-Farber Cancer Institute

De-escalating Treatment in the Adjuvant Setting in HER2-Positive Disease

Karen A. Gelmon, MD—Chair

British Columbia Cancer Agency

Therapeutic Challenges in the Metastatic Setting for Patients With HER2-Positive Metastatic Breast Cancer

 

Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer

Nadine Jackson McCleary, MD

Dana-Farber Cancer Institute

Tailoring Adjuvant Therapy for Geriatric Population

Al Bowen Benson, MD—Chair

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Adjuvant Therapy for Rectal Cancer and Stage IV Post Metastectomy

Rodrigo Dienstmann, MD

Oncology Data Science Group (ODYSSEY)

Molecular Profiles and the Future of Adjuvant Therapy

 

Systemic Therapy of Advanced Inoperable Melanoma

Caroline Robert, MD, PhD

Institut Gustave Roussy

Checkpoint Inhibitor Immunotherapy

Paul B. Chapman, MD

Memorial Sloan Kettering Cancer Center

Molecularly Targeted Therapy

Ragini Reiney Kudchadkar, MD—Chair

Winship Cancer Institute, Emory University

Options for Patients Who Progress After Targeted and Checkpoint Inhibitor Therapy

 

Meet the Professor Sessions

 Challenging Clinical Scenarios in Myeloproliferative Neoplasms 

Ronald Hoffman, MD

The Tisch Cancer Institute

Managing Challenging Problems in Myeloproliferative Neoplasms

 

 Role of Prophylactic Cranial Irradiation and Thoracic Radiation Therapy in Patients With Extensive-Stage Small Cell Lung Cancer 

Elizabeth Gore, MD

Medical College of Wisconsin

A Discussion of the Role of PCI and Thoracic RT in Patients With Extensive-Stage Small Cell Lung Cancer

Ben J. Slotman, MD, PhD

VU University Medical Center

Role of Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: A Discussion

1:15 PM–2:45 PM

 

 

Clinical Science Symposia

Geriatric Oncology

Sarcoma

1:15 PM–4:15 PM

Oral Abstract Session

Developmental Therapeutics—Immunotherapy

1:15 PM–4:45 PM

Poster Sessions

Cancer Prevention, Genetics, and Epidemiology

Central Nervous System Tumors

Genitourinary (Prostate) Cancer

Head and Neck Cancer

Health Services Research, Clinical Informatics, and Quality of Care

3:00 PM–4:15 PM

Award Lecture

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

 

Poster Discussion Session

Hematologic Malignancies—Plasma Cell Dyscrasia

 

Education Sessions

Addressing the Survivorship Care Needs of Patients on Extended Cancer Therapies

Paul B. Jacobsen, PhD—Chair

Moffitt Cancer Center

Survivorship Care Needs of Patients Receiving Extended Cancer Treatment

Patricia A. Ganz, MD, FASCO

University of California, Los Angeles

The Changing Face of Cancer Survivorship: Overview of Extended Therapies Used to Prevent Recurrence and Control Disease

Ryan David Nipp, MD

Massachusetts General Hospital 

Integrating Palliative Care Into Survivorship Care for Patients Undergoing Extended Cancer Treatment

 

Advances in the Treatment of Pediatric Bone Sarcomas

Katherine A. Janeway, MD—Chair

Dana-Farber Cancer Institute

The Case for Phase II Clinical Trials to Identify Novel Therapies for Osteosarcoma

Patrick Grohar, MD, PhD

Van Andel Institute

Translocation-Positive Ewing Sarcoma: An Opportunity for Targeted Therapy

Joshua David Schiffman, MD

University of Utah

The Evidence for Clinical Cancer Genetic Testing for All Pediatric Patients With Cancer

 

ASCO/Society of Nuclear Medicine and Molecular Imaging (SNMMI) Joint Session: Recent Advances in Nuclear Imaging in Prostate Cancer—Implications for Treatment

Daniel F. Hayes, MD, FASCO—Chair

University of Michigan Comprehensive Cancer Center

Breast Cancer in the Central Nervous System

Laurie E. Gaspar, MD, MBA

University of Colorado Cancer Center

Whole-Brain Radiation Therapy Versus More Focal Approaches: How Do You Choose?

Riccardo Soffietti, MD

San Giovanni Battista University Hospital

Neuro-Oncology Perspective of Treatment Options in Metastatic Breast Cancer

Nancy U. Lin, MD—Chair

Dana-Farber Cancer Institute

The Role of Systemic Therapy in Central Nervous System Disease

 

Clinical Pathways and New Drug Approvals: Maximizing Value Without Compromising Patient Care

Edward S. Kim, MD—Chair

Levine Cancer Institute-Carolinas HealthCare System

The Role of Clinical Pathways in Integrating New Drugs Into Practice

Eric S. Nadler, MD

Texas Oncology

When Expensive Marginal Drugs Should Not Be Used: How to Assess Benefit Versus Cost

Janet Freeman-Daily, MS

Independent Lung Cancer Patient Advocate

Cost-Benefit From a Patient Perspective: Incremental Benefit Is Worth It

 

Diagnostics in Sarcoma: The Pathologist Is the Clinician's Best Friend

Min S. Park, MD—Chair

Swedish Cancer Institute

Sarcoma Pathology: Needs of the Practicing Medical Oncologist

Khin Thway, MD

The Royal Marsden NHS Foundation Trust

Discrepancies in Pathology Reporting

Andrew Rosenberg, MD

Sylvester Comprehensive Cancer Center

Bone Sarcoma Pathology: Diagnostic Approach for Optimal Therapy

 

More Medicine, Fewer Clicks: How Informatics Can Actually Help Your Practice

Jeremy Warner, MD, MS—Chair

Vanderbilt-Ingram Cancer Center

Integrating External Knowledge Into the Oncology Workflow

Elmer Victor Bernstam, MD, MS

The University of Texas School of Biomedical Informatics

The Challenges of Clinical Documentation in the Twenty-First Century

Debra A. Patt, MD, MPH, MBA

McKesson Specialty Health–The US Oncology Network

Creating an Informatics-Enabled Oncology Practice

Joshua Mandel, MD

Harvard Medical School

Digital Donations: Patient Consent and Enabling Technologies in the Era of Electronic Health Records

 

Meet the Professor Sessions

 Integrating Cancer Rehabilitation Into Global Oncology Care: The Experience of Two Cancer Centers 

Michael Dean Stubblefield, MD

Kessler Institute for Rehabilitation

Comprehensive Rehabilitation in the United States

Miranda Velthuis, PhD

Comprehensive Cancer Centre

Comprehensive Rehabilitation in the Netherlands

 

 Sequencing Therapy in Metastatic Renal Cell Carcinoma: How Does the Clinician Choose Treatment? 

Stephen Boyd Riggs, MD

Levine Cancer Institute-Carolinas HealthCare System

Role of Cytoreductive Nephrectomy in the Era of Targeted and Immunotherapy

3:00 PM–6:00 PM

Oral Abstract Session

Gastrointestinal (Colorectal) Cancer

4:45 PM–6:00 PM

Poster Discussion Sessions

Cancer Prevention, Genetics, and Epidemiology

Central Nervous System Tumors

Developmental Therapeutics—Immunotherapy

Genitourinary (Prostate) Cancer

Head and Neck Cancer

Health Services Research, Clinical Informatics, and Quality of Care

 

Education Sessions

Are We Gaining Any Ground in Myelodysplastic Syndromes?

Eric James Duncavage, MD

Barnes-Jewish Hospital

Recent Insights Into the Biology of Myelodysplastic Syndrome

Rafael Bejar, MD, PhD

Moores Cancer Center

What We Need to Know About Risk Stratification in Myelodysplastic Syndromes

Alan F. List, MD—Chair

Moffitt Cancer Center

Emergence of Molecularly Guided Therapy in Myelodysplastic Syndromes

 

ASCO Book Club

Lung Cancer in the Older Population: Caring for the Whole Patient

Corey J. Langer, MD

University of Pennsylvania Abramson Cancer Center

Approach to the Older Patient With Lung Cancer: Science and Art

Craig H. Reynolds, MD—Chair

Florida Cancer Affiliates

On Doing Nothing: Care of the Dying Patient From a Cultural Perspective

Carolyn Jean Presley, MD

Smilow Cancer Hospital

Supportive Care and Decision Making in Thoracic Oncology in a Time of Therapeutic Enthusiasm

 

Optimal Adjuvant Radiation and the Upstream and Downstream Treatment Implications

Robert Mutter, MD

Mayo Clinic

Indications and Implications of Adjuvant Radiation Therapy: How Has the Radiation Oncologist's Perspective Changed?

Henry Mark Kuerer, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center

The Breast Surgeon's Perspective: How Planned Radiation Will Impact Management of the Axilla in Patients Who Undergo Mastectomy and Breast Conservation

Peter Cordeiro, MD

Memorial Sloan Kettering Cancer Center 

The Plastic Surgeon's Perspective: Reconstruction Implications of Post-Mastectomy Radiation Therapy

 

Meet the Professor Sessions

 Bone Disease in Myeloma 

Noopur S. Raje, MD

Massachusetts General Hospital

Going Beyond Bisphosphonates in Myeloma Bone Disease

G. David Roodman, MD, PhD

Indiana University

Going Beyond Bisphosphonates in Myeloma Bone Disease

 

Challenges in Building International Pediatric Oncology Programs

Carlos Rodriguez-Galindo, MD

St. Jude Children's Research Hospital